Male Stress Urinary Incontinence
Male stress urinary incontinence (SUI) most commonly results from sphincteric insufficiency following radical prostatectomy, radiation therapy, TURP, or trauma to the external urethral sphincter. Treatment selection depends on incontinence severity (pad count, pad weight), prior radiation, urethral health, patient dexterity, and preference. For men with SUI after prostate treatment and prior urethral reconstruction, AUA/GURS/SUFU says AUS may be offered with counseling that complication rates are higher ; the guideline considers slings ineffective after most posterior or anterior urethral reconstructions.[1] Options range from conservative (pelvic floor rehabilitation, penile compression) to surgical (slings, adjustable devices, AUS).
Decision Framework
Pelvic-floor muscle training (PFMT) is an early conservative option after prostate treatment, with benefits for the pace of recovery; the incremental value of electrical stimulation is less certain and it is not required.[1][2] For bothersome SUI after prostate treatment that is not improving despite conservative therapy, the AUA/GURS/SUFU guideline permits surgery as early as six months and recommends offering surgery at one year if bothersome SUI persists despite conservative therapy.[1] For SUI surgery after prostate treatment, AUA/GURS/SUFU recommends cystourethroscopy to identify stricture, bladder-neck contracture and bladder pathology that can change or abort the operation; it permits urodynamics when this may clarify diagnosis or counseling .[1] Treat symptomatic vesicourethral anastomotic stenosis or bladder-neck contracture before continence surgery ; after VUAS treatment, repeat cystourethroscopy at least 4–6 weeks later to document improvement and stability.[1] For men with urinary incontinence, EAU 2026 strongly recommends a validated symptom score, bladder diary, pad-weight test and post-void residual measurement and weakly recommends invasive urodynamics when invasive treatment is considered.[2]
AUA/GURS/SUFU 2024 recommends discussing AUS for mild-to-severe SUI , describes it as the most predictable and reliable option, and recommends counseling that effectiveness likely declines over time and reoperation is common.[1] Before implantation, confirm that the patient has the physical and cognitive ability to operate the AUS pump .[1] In the single-arm AUSCO trial, 91/97 (94%) achieved ≥50% pad-weight reduction and 61/101 (60%) reported zero pad use at 12 months after device activation.[4] In a French first-implant cohort of 8,475 men, reintervention-free survival was 71%, 57% and 40% at 2, 5 and 10 years, respectively (Lenfant 2025).[5] In the MASTER RCT (n = 380), a fixed male sling met its prespecified 12-month noninferiority margin against AUS on a strict any-leakage endpoint, but 87.0% versus 84.2% still reported some incontinence, and several secondary symptom and satisfaction outcomes favored AUS.[3] At 24 months, the trial's secondary continence analysis met noninferiority under the strict no-leakage definition (21/140 sling versus 22/148 AUS) but not under the less-strict definition (44/140 versus 51/148).[13][14] Further surgery occurred in 20 sling (11%) versus 4 AUS (2%) recipients.[13][14] Fixed slings remain an option for selected mild-to-moderate non-radiated SUI; severe leakage and prior radiation are associated with poorer sling results.[1][2] EAU also advises counseling that prior transurethral surgery may worsen nonadjustable sling outcomes .[2] A 2025 systematic review of 62 cohorts (5,696 men after prostate surgery) graded the associations of irradiation, greater pad use and greater 24-hour urine loss with fixed-sling failure as high certainty, and those of prior urethral stricture, previous incontinence therapy, detrusor overactivity, higher MSIGS score and an unfavorable repositioning test as moderate certainty.[16] ATOMS is an adjustable option, including after failed fixed slings in observational series, but head-to-head evidence has not established superior outcomes from adjustability.[2][6] Male urethral bulking has limited, heterogeneous evidence and a niche role; the guideline gives a strong recommendation to counsel that efficacy is low and cure is rare.[1][2]
Treatment Selection by Clinical Scenario
The pad-per-day bands below are practical orientation; pad weight, degree of bother, radiation history, urethral condition and patient goals can change the choice.[1][2] Device percentages from different cohorts lack direct head-to-head comparison. EAU recommends offering AUS or ProACT implantation only in expert centres .[2]
| Clinical Scenario | First-Line Surgical Option | Alternative(s) | Avoid |
|---|---|---|---|
| Mild SUI (1–2 PPD), no prior radiation | Discuss fixed sling — AdVance / AdVance XP or AUS (AMS-800) [1] | ATOMS (adjustable); ProACT | — |
| Moderate SUI (3–4 PPD), no prior radiation | AUS (AMS-800) preferred | ATOMS or AdVance XP (Sacco matched cohort enrolled men using 3–5 PPD: at 12 months, 0–1 PPD in 94.3% with AUS vs 68.6% with TiLOOP Male retrourethral transobturator sling)[7] | Fixed sling alone in radiation history |
| Severe SUI (≥ 5 PPD) | AUS (AMS-800) | ProACT balloons in selected non-radiated men with SUI after prostate treatment who accept possible serial adjustments and explantation risk .[1] | Routine fixed sling; bulking agents |
| Mild-moderate SUI, unsuitable for or declines major surgery | Containment options; discuss limited-evidence urethral bulking if appropriate | ProACT periurethral balloons only if the patient accepts an implanted device and its adjustment/revision risks, without prior pelvic radiation[1][2] | Presenting ProACT as a non-implant or nonsurgical option |
| SUI with prior pelvic radiation | AUS (AMS-800) preferred; counsel that radiation is associated with higher AUS erosion and explantation risk.[1][2] | ATOMS (Doiron multicenter series: continence 62.5% after prior radiation vs 87.9% without)[10] | Fixed sling — radiation is a strong failure predictor |
| Recurrent SUI after failed fixed sling | Reassess severity, urethral health and cause, then recommend AUS (AMS-800) [1] | ATOMS in selected patients (Queissert retrospective cohort: 76.1% social continence at mean 42.5 mo after failed AdVance)[6] | Automatic repeat fixed sling |
| Recurrent SUI after failed AUS | Evaluate mechanical failure, erosion, tissue/urethral status and bladder function, then discuss AUS revision or replacement [1] | Cuff or component strategies, including selected tandem-cuff salvage, depend on the failure mechanism; see the AUS page | Assuming every recurrence is urethral atrophy |
| Concomitant SUI + erectile dysfunction | Select SUI surgery by severity and urethral factors; when both operations are indicated, discuss AUS + penile prosthesis concomitantly or in stages . One study reported longer operative time with combined implantation; a separate observational database study associated combined implantation with more reoperations than penile prosthesis implantation alone.[1] | Sling + penile prosthesis in selected men | — |
| Mixed incontinence (SUI + urgency / OAB) | Characterize the stress and urgency contributions; address bothersome urgency via the OAB / UUI pathway while planning SUI treatment | Reassess both symptom components and patient priorities after each intervention | Assuming urgency must resolve completely before SUI treatment |
| End-stage urethra after recurrent AUS erosion, accepts chronic SPT | Perineal permanent urethral ligation (PUL) | Bladder-neck closure + continent catheterizable channel | Repeat cuff placement in a non-salvageable urethra |
| Devastated outlet; SPT pathway unacceptable; bladder preservation feasible | Discuss bladder-neck closure + continent catheterizable channel if reliable channel catheterization is feasible; this combined approach has been described in a small mixed series including men after prostatectomy.[19] | Urinary diversion | Continued failed reconstruction |
| Devastated outlet with hostile bladder | Discuss urinary diversion, including cystectomy with ileal conduit or continent catheterizable pouch as appropriate .[1] | — | Continued failed reconstruction |
Sling / Adjustable Device Sub-Comparison
| Feature | Fixed Sling (AdVance XP) | Adjustable (ATOMS) | Adjustable (Argus) | ProACT Balloons |
|---|---|---|---|---|
| Mechanism | Sphincter repositioning | Cushion compression + adjustable | Suburethral compression + adjustable | Periurethral balloon compression |
| Best indication | Selected mild-moderate, non-radiated | Selected cases, including observational salvage after failed sling | Selected cases; limited heterogeneous data | Selected non-radiated cases; high revision burden |
| Reported continence or success (definitions and follow-up vary) | Across 15 cohorts of several male-sling designs (758 men), 470/758 (62%) met study-specific cure definitions (range 34–91%)[1] | 68% pooled study-defined dryness in observational cohorts (definitions included 0–1 safety pad/day, zero pads, and pad-weight thresholds; mean ATOMS follow-up 20.8 mo)[8]; 80% study-defined continence at median 9 mo in a 160-man cohort[10] | 72% composite success (cured or improved; 68/95) at median 27 mo, not a dry-rate estimate[11] | 60.2% study-defined dryness across 13 studies (667 men) in a 19-study review (1,264 men overall; overall mean follow-up 3.6 years)[12]; 55.1% using 0–1 pads/day in an updated 18-study synthesis (1,570 men; mean follow-up 34.7 months)[17] |
| Postop adjustability | No | Yes (scrotal port) | Yes (silicone washer tensioning)[15] | Yes (scrotal port) |
| Explant rate | Low in selected cohorts; erosion is exceedingly rare[1] | ~5% across observational ATOMS cohorts (mean follow-up 20.8 mo)[8] | Model- and study-dependent; counsel on erosion, pain and explant risk | ~24% across observational ProACT cohorts (mean follow-up 30.6 mo; nonmatched comparison)[8]; 27% all-cause (range 7–55%) in the guideline review[1] |
| Prior-radiation tolerance | Reduced; prior pelvic radiotherapy may worsen nonadjustable male sling outcomes[1][2] | Lower study-defined continence after prior radiotherapy (62.5% vs 87.9% without radiotherapy; median follow-up 9 months)[10] | Limited data | Do not offer ProACT after pelvic radiotherapy ; AUA adjustable-balloon selection is for non-radiated men.[1][2] |
| Use after failed sling | Selected repeat cases require individual assessment | Reported in observational series; not proven superior to AUS | Limited data | Limited data |
AUS vs Sling Snapshot
- MASTER RCT (Abrams 2021, n = 380): male sling met the 12-month noninferiority criterion (87.0% versus 84.2% remained incontinent under a strict any-leakage definition; continence-success risk difference −3.6 percentage points, sling minus AUS, 95% CI −11.6 to 4.6, within the noninferiority margin; the abstract prints the same difference with a positive sign); the ICIQ-UI SF mean difference at 12 months was 1.4 (95% CI 0.2 to 2.6) in the 2021 article versus 1.30 (95% CI 0.11 to 2.49, p = 0.032) in the full HTA report — the same comparison, both favoring AUS.[3][14] In the 2021 article, 6 sling recipients had serious adverse events, while 11 AUS recipients had 13 serious adverse events; the full HTA report counts 8 of 180 sling and 13 of 175 AUS recipients (15 AUS events because one man had three), a difference that was uncertain.[14] At 24 months, further surgery occurred in 20 sling (11%) versus 4 AUS (2%) recipients; the ICIQ-UI SF mean difference was 1.4 (95% CI 0.2 to 2.6) favoring AUS.[13]
- AUSCO trial (Kaufman, 115 implanted at 17 sites): in this single-arm study, 91/97 (94%) achieved ≥50% pad-weight reduction and 61/101 (60%) reported zero pad use at 12 months after device activation; 9/115 (7.8%) underwent device revision (mechanical malfunction 3, erosion 2, none for infection) and 15% had a serious adverse event.[4]
- Sacco 2021 propensity match (moderate PPI): AUS 94.3% versus fixed sling 68.6% using 0–1 pad/day at 12 mo in 35 matched men per arm.[7]
- Geretto 2023 propensity match (AUS versus ATOMS, retrospective, 49 per arm): AUS dryness 44.9% versus 22.5%, but more high-grade complications and reinterventions; Estimated 60-month freedom from explantation was 82% with ATOMS versus 67% with AUS (p = 0.03); freedom from any reintervention was 67% versus 53% (p = 0.11).[9]
- Lenfant 2025 French first-implant national database (n = 8,475): AUS reintervention-free survival 71% / 57% / 40% at 2 / 5 / 10 yr; this endpoint includes removal or replacement, not only mechanical device failure.[5]
Treatment Options and Salvage
- Conservative therapy. PFMT and appropriate behavioral measures; biofeedback or electrical stimulation are selective adjuncts, not requirements. Reassess recovery and bother over time; for bothersome SUI after prostate treatment that is not improving despite conservative therapy, surgery may be offered as early as six months.[1][2]
- Containment. penile clamp, condom catheter, pads (combination strategy preferred)
- AUS (AMS-800). Mild-to-severe SUI; preferred for irradiated patients and after failed sling
- Fixed male sling (AdVance / AdVance XP; Virtue: mild-to-moderate SUI without radiation
- Periurethral balloons (ProACT) or adjustable sling (ATOMS, Argus, REMEEX): selected alternatives with device-specific evidence, adjustment and explantation trade-offs; the AUA/GURS/SUFU guideline limits adjustable balloons to non-radiated men and EAU advises against ProACT after pelvic radiation .[1][2] The FDA ProACT physician IFU indicates the device for adult men with intrinsic-sphincter-deficiency SUI lasting at least 12 months after radical prostatectomy or TURP despite conservative therapy; contraindications include incontinence due to detrusor overactivity, reduced bladder compliance, and postvoid residual >100 mL.[18] In the FDA pivotal cohort, bladder or urethral perforation occurred during implantation in 19/123 men (15.4%).[18]
- Urethral bulking. Niche role, mild SUI in poor surgical candidates
- AUS reassessment / individualized revision. Identify erosion, infection, mechanical failure, tissue/urethral changes and bladder dysfunction before selecting a salvage method
- Perineal permanent urethral ligation (PUL). End-stage urethra after failed / eroded AUS when chronic SPT drainage is acceptable
- Bladder-neck closure / urinary diversion. Last resort when PUL is unsuitable or the bladder / drainage plan also requires reconstruction
For mixed incontinence with an OAB / urgency component, assess both components and treat bothersome urgency through the OAB & UUI database while planning SUI management; reassess after each step. OAB pharmacotherapy targets urgency, not pure sphincteric male SUI.
| Treatment | Category | Best for / indication |
|---|---|---|
| Pelvic Floor Muscle Training (PFMT) | Conservative | Early conservative option after prostate treatment; duration and escalation depend on recovery and bother. |
| Biofeedback Therapy (BFT) | Conservative | Adjunct to PFMT in early postop period; patients unable to isolate the sphincter. |
| Pelvic Floor Electrical Stimulation | Conservative | Selective PFMT adjunct; short-term benefit uncertain and not required for every patient. |
| Behavioral & Lifestyle Modifications | Conservative | Tailor fluid and caffeine intake, constipation, and smoking advice to the patient when relevant. |
| Weight Loss | Conservative | Weight management when appropriate; benefit threshold for male post-prostate-treatment SUI is uncertain. |
| Penile Clamp (External Compression Device) | Conservative | Short daytime activities when correctly fitted and released at prescribed intervals; intact sensation and dexterity required. |
| Condom Catheter (External Sheath) | Conservative | Extended activities or overnight urine containment when bladder emptying is adequate; selected SCI reflex voiders only after bladder-risk assessment. External sheaths collect voided urine but do not treat urinary retention (see linked condom-catheter page). |
| Absorbent Pads | Conservative | Everyday / overnight wear, often combined with a clamp or sheath for activities. |
| Duloxetine | Conservative | Men with SUI considering medication; EAU Weak offer, with Strong counseling on adverse effects and off-label status in Europe [2]. |
| Urethral Bulking Agents | Periurethral Bulking | Niche — mild SUI in poor surgical candidates declining more invasive options. |
| AdVance / AdVance XP Sling | Compressive Sling — Fixed | Mild-to-moderate SUI (≤ 3 PPD), no prior radiation; surgical option for selected patients. |
| Virtue Quadratic Sling | Compressive Sling — Fixed | Mild-to-moderate SUI; alternative to AdVance when fixation can be optimized. |
| ATOMS (Adjustable Transobturator Male System) | Compressive Sling — Adjustable | Selected mild-to-moderate or post-sling cases; observational salvage data, no proven comparative superiority from adjustability. |
| Argus Sling (Classic / T) | Compressive Sling — Adjustable | Largely superseded by ATOMS; consider only at experienced high-volume centers. |
| REMEEX (Male Readjustable Sling, MRS) | Compressive Sling — Adjustable | Niche when repeat tension adjustment is a priority. |
| ProACT Periurethral Balloons | Periurethral Balloon | Selected non-radiated SUI when an adjustable implanted device and revision risk are acceptable. |
| Artificial Urinary Sphincter (AMS-800) | Sphincter | Mild-to-severe SUI; preferred after pelvic radiation or a failed sling; most predictable and reliable option. |
| AUS Revision / Tandem Cuff | Sphincter | Recurrent SUI after AUS, following evaluation of device, urethra, erosion/infection and bladder function. |
| Perineal Permanent Urethral Ligation (PUL) | Salvage | End-stage urethra with severe refractory SUI after recurrent AUS erosion; chronic SPT acceptable. |
| Bladder-Neck Closure + Catheterizable Channel | Salvage | Devastated outlet after multiple AUS failures or intractable bladder-neck contracture when bladder preservation is feasible and reliable catheterization through the channel is planned (AUA/GURS/SUFU ref. 1); consider when PUL is unsuitable. |
| Urinary Diversion | Salvage | Last resort — intractable incontinence with non-functional outlet. |
Videos
References
1. Breyer BN, Kim SK, Kirkby E, et al. Updates to Incontinence After Prostate Treatment: AUA/GURS/SUFU Guideline (2024). J Urol. 2024;212(4):531-538. doi:10.1097/JU.0000000000004088. Statements and discussion cited from the unabridged guideline (2019; amended 2024). 2. European Association of Urology. Management of Non-neurogenic Male LUTS, disease management: urinary incontinence. Accessed September 2026. 3. Abrams P, et al. MASTER randomized trial. Eur Urol. 2021;79:812–823. doi:10.1016/j.eururo.2021.01.024 4. Kaufman MR, et al. The Artificial Urinary Sphincter Clinical Outcomes Trial: Primary Results. J Urol. 2026;215:194–202 (online 2025). Single-arm prospective trial. doi:10.1097/ju.0000000000004796 5. Lenfant L, et al. Artificial urinary sphincter implants in men: a national health care data system-based study to assess reinterventions in France. J Urol. 2025;213:217–227. doi:10.1097/ju.0000000000004285 6. Queissert F, et al. ATOMS is an effective and safe second-line treatment option for recurrent urinary incontinence after implantation of an AdVance/AdVance XP fixed male sling? A multicenter cohort analysis. J Clin Med. 2022;11:81. doi:10.3390/jcm11010081 7. Sacco E, et al. AUS versus fixed sling for moderate post-prostatectomy SUI: propensity-matched study. BJU Int. 2021;127:229–237. doi:10.1111/bju.15197 8. Angulo JC, Schönburg S, Giammò A, Abellán FJ, Arance I, Lora D. "Systematic review and meta-analysis comparing Adjustable Transobturator Male System (ATOMS) and Adjustable Continence Therapy (ProACT) for male stress incontinence." PLoS One. 2019;14(12):e0225762. Observational studies only. doi:10.1371/journal.pone.0225762 9. Geretto P, et al. Comparison study between artificial urinary sphincter and adjustable male sling: a propensity-score-matched analysis. J Clin Med. 2023;12:5489. doi:10.3390/jcm12175489 10. Doiron RC, et al. Canadian experience with the Adjustable Transobturator Male System for post-prostatectomy incontinence: a multicenter study. J Urol. 2019;202:1022–1028. doi:10.1097/ju.0000000000000420 11. Bochove-Overgaauw DM, Schrier BP. An adjustable sling for the treatment of all degrees of male stress urinary incontinence: retrospective evaluation of efficacy and complications after a minimal followup of 14 months. J Urol. 2011;185:1363–1368. doi:10.1016/j.juro.2010.11.075 12. Larson T, Jhaveri H, Yeung LL. Adjustable continence therapy (ProACT) for the treatment of male stress urinary incontinence: a systematic review and meta-analysis. Neurourol Urodyn. 2019;38:2051–2059. doi:10.1002/nau.24135 13. Constable L, Drake MJ, Cooper D, et al. The 24-mo outcomes from the MASTER noninferiority randomised controlled trial. Eur Urol Focus. 2026 (online 26 August). 14. Constable L, Abrams P, Cooper D, et al. Synthetic sling or artificial urinary sphincter for men with urodynamic stress incontinence after prostate surgery: the MASTER non-inferiority RCT. Health Technol Assess. 2022;26(36):1–152. 15. Yanaral F, Gültekin MH, Halis A, Akbulut F, Sarilar O, Ozgor F. "Adjustable male sling for the treatment of postprostatectomy stress urinary incontinence: intermediate-term follow-up results." Cureus. 2023;15(8):e43280. doi:10.7759/cureus.43280 16. Sacco E, Campetella M, Marino F, et al. "Preoperative risk factors for failure after fixed sling implantation for postprostatectomy stress urinary incontinence (FORESEE): a systematic review and meta-analysis." Eur Urol Open Sci. 2025;77:58-77. doi:10.1016/j.euros.2025.05.012 17. Tricard T, Song QX, Munier P, et al. "Adjustable continence therapy (proACT) for the treatment of male stress urinary incontinence post-prostatectomy: a systematic review and meta-analysis (2023 update)." World J Urol. 2023;41(7):1793-1802. doi:10.1007/s00345-023-04452-6
18. U.S. Food and Drug Administration. "ProACT Adjustable Continence Therapy for Men: Physician Instructions for Use." P/N 900136 Rev. A, PMA P130018 (approved 2015). FDA physician IFU.
19. Spahn M, Kocot A, Loeser A, Kneitz B, Riedmiller H. "Last resort in devastated bladder outlet: bladder neck closure and continent vesicostomy--long-term results and comparison of different techniques." Urology. 2010;75(5):1185-1192. doi:10.1016/j.urology.2009.11.070.